Literature DB >> 22090174

Vaccines and immunomodulatory therapies for food allergy.

Jay A Lieberman1, Anna Nowak-Węgrzyn.   

Abstract

The apparent increase in food allergy prevalence has led to a surge in the amount of clinical and basic science research dedicated to the field. At the current time, allergen avoidance remains the cornerstone of treatment; however, recent clinical trials investigating various forms of immunotherapy have opened doors to the possible future application of an active treatment strategy in everyday practice. In addition, improvements in molecular biology have allowed researchers to purify, clone, and modify allergens, thus laying the groundwork for research on vaccines using modified proteins of decreased allergenicity. Finally, various allergen-nonspecific immunomodulatory therapies are also being investigated as a means to alter the immune response to food allergens. With these emerging therapeutic strategies, it is hoped that practitioners will have options in caring for their food-allergic patients in the near future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22090174     DOI: 10.1007/s11882-011-0232-5

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  62 in total

1.  A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebo-controlled food challenge.

Authors:  S T H P Bolhaar; L Zuidmeer; Y Ma; F Ferreira; C A F M Bruijnzeel-Koomen; K Hoffmann-Sommergruber; R van Ree; A C Knulst
Journal:  Clin Exp Allergy       Date:  2005-12       Impact factor: 5.018

2.  The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.

Authors:  C Alexander; M Tarzi; M Larché; A B Kay
Journal:  Allergy       Date:  2005-10       Impact factor: 13.146

3.  Sublingual immunotherapy for cow's milk protein allergy: a preliminary report.

Authors:  D de Boissieu; C Dupont
Journal:  Allergy       Date:  2006-10       Impact factor: 13.146

4.  Specific oral tolerance induction in children with very severe cow's milk-induced reactions.

Authors:  Giorgio Longo; Egidio Barbi; Irene Berti; Rosanna Meneghetti; Angela Pittalis; Luca Ronfani; Alessandro Ventura
Journal:  J Allergy Clin Immunol       Date:  2007-12-26       Impact factor: 10.793

5.  A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy.

Authors:  Hugh A Sampson; Donald Y M Leung; A Wesley Burks; Gideon Lack; Sami L Bahna; Stacie M Jones; Dennis A Wong
Journal:  J Allergy Clin Immunol       Date:  2011-03-11       Impact factor: 10.793

6.  Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen.

Authors:  Masako Toda; Gerald Reese; Gabriele Gadermaier; Veronique Schulten; Iris Lauer; Matthias Egger; Peter Briza; Stefanie Randow; Sonja Wolfheimer; Valencia Kigongo; Maria Del Mar San Miguel Moncin; Kay Fötisch; Barbara Bohle; Stefan Vieths; Stephan Scheurer
Journal:  J Allergy Clin Immunol       Date:  2011-05-14       Impact factor: 10.793

7.  Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model.

Authors:  Xiu-Min Li; Kamal Srivastava; James W Huleatt; Kim Bottomly; A Wesley Burks; Hugh A Sampson
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

8.  Open-label maintenance after milk oral immunotherapy for IgE-mediated cow's milk allergy.

Authors:  Satya D Narisety; Justin M Skripak; Pamela Steele; Robert G Hamilton; Elizabeth C Matsui; A Wesley Burks; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2009-08-08       Impact factor: 10.793

9.  Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization.

Authors:  Christophe P Frossard; Lothar Steidler; Philippe A Eigenmann
Journal:  J Allergy Clin Immunol       Date:  2007-02-20       Impact factor: 10.793

10.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

Authors:  U Müller; C A Akdis; M Fricker; M Akdis; T Blesken; F Bettens; K Blaser
Journal:  J Allergy Clin Immunol       Date:  1998-06       Impact factor: 10.793

View more
  3 in total

Review 1.  Peptide and Recombinant Allergen Vaccines for Food Allergy.

Authors:  Quindelyn S Cook; A Wesley Burks
Journal:  Clin Rev Allergy Immunol       Date:  2018-10       Impact factor: 8.667

Review 2.  Food allergy diagnosis and therapy: where are we now?

Authors:  Aleena Syed; Arunima Kohli; Kari C Nadeau
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

Review 3.  Anaphylaxis avoidance and management: educating patients and their caregivers.

Authors:  Kirsi M Järvinen; Jocelyn Celestin
Journal:  J Asthma Allergy       Date:  2014-07-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.